Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Barrett, Rachel M.A.; Osborne, Toby P.; Wheatley, Sally P. (2009)
Languages: English
Types: Article
Subjects: QR

Classified by OpenAIRE into

mesheuropmc: neoplasms
Survivin is an essential chromosomal passenger protein required for mitotic progression. It is also an inhibitor of apoptosis and can prevent caspase-mediated cell death. In addition, survivin levels are elevated in cancer cells where its presence correlates with increased resistance to chemo- and radio-therapy, which makes it an attractive target for novel anti-cancer strategies. Interestingly, survivin is phosphorylated by the mitotic kinase, cdk1, and a non-phosphorylatable form, survivin(T34A), cannot inhibit apoptosis. Here we rigorously test the ability of survivin(T34A) and its corresponding phosphomimetic, survivin(T34E), to promote cell viability through survivin's dual roles. The effects of these mutations are diametrically opposed: survivin(T34A) accelerates cell proliferation and promotes apoptosis, whereas survivin(T34E) retards growth and promotes survival. Thus the phosphorylation status of survivin at T34 is pivotal to a cell's decision to live or die.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-57.
    • 2. Colnaghi R, Connell CM, Barrett RMA, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 281:33450-6.
    • 3. Connell CM, Colnaghi R, Wheatley SP. Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem 2008; 238:3289-96.
    • 4. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65:4881-7.
    • 5. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8:61-70.
    • 6. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273:11177-82.
    • 7. Shin S, Sung B-J, Cho Y-S, Kim H-J, Ha MC, Hwang J-I, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40:1117-23.
    • 8. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7:602-8.
    • 9. Jahnke U, Higginbottom K, Newland AC, Cotter FE, Allen PD. Cell death in leukemia: Passenger protein regulation by topoisomerase inhibitors. Biochem Biophys Res Comm 2007; 361:928-33.
    • 10. O'Connor DS, Grossman D, Plescia J, Li FZ, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34(cdc2) phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97:13103-7.
    • 11. O'Connor DS, Wall NR, Porter ACG, Altieri DC. A p34cdc2 survival checkpoint in cancer. Cancer Cell 2002; 2:43-54.
    • 12. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumour cell apoptosis. Cancer Res 2003; 63:230-5.
    • 13. Lens SMA, Rodriguez JA, Vader G, Span SW, Giaccone G, Medema RH. Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biology of the Cell 2006; 17:1897-909.
    • 14. Temme A, Rieger M, Reber F, Lindemann D, Weigle B, Diestelkoetter-Bachert P, et al. Localization, dynamics and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 2003; 14:78-92.
    • 15. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in response to loss of spindle tension in HeLa cells. J Cell Sci 2003; 116:2987-98.
    • 16. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003; 22:2934-47.
    • 17. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108:981-90.
    • 18. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98:635-40.
    • 19. Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/Cyclin B1 protects mitotic cells against apoptosis. Molecular Cell 2007; 26:301-10.
    • 20. Wheatley SP, Barrett RMA, Andrews PD, Medema RH, Morley SJ, Swedlow JR, et al. Phosphorylation of aurora-B negatively regulates survivin function during mitosis. Cell Cycle 2007; 6:1220-30.
    • 21. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ferrigno PK, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006; 281:1286-95.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article